fMRI Study Examining Effects of D-cycloserine in Specific Phobia

Completed · Phase 2 · Has a placebo group

Conditions studied: Phobias

In brief

The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.

Key facts

Study ID

NCT00591825

Run by

University of Kansas Medical Center

People needed

54

Starts

2006-03-01

Expected to finish

2012-12-01

Last updated by the study team

2017-06-05

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Right-handed
• Adults between 18 and 55 years of age
• Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia.
• Individuals of both genders and all races will be included

You may not qualify if…

• Women who are breastfeeding or pregnant
• Individuals with medical conditions unsuitable for MR scanning
• Individuals reporting a history of epilepsy or seizures
• Individuals reporting an allergy to cycloserine
• Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event
• Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury *Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia)
• Individuals currently taking any psychotropic medication

Where it is running

• University of Kansas Medical Center, Hoglund Brain Imaging Center — Kansas City, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.